

# Otenabant

**Catalog No: tcsc1279**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

686344-29-6

**Formula:**

$C_{25}H_{25}Cl_2N_7O$

**Pathway:**

GPCR/G Protein

**Target:**

Cannabinoid Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

CP-945598

**Observed Molecular Weight:**

510.42


## Product Description

Otenabant is a potent and selective **cannabinoid receptor CB1** antagonist with  $K_i$  of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

IC50 & Target:  $K_i$ : 0.7 nM (CB1)

**In Vitro:** Otenabant HCl has low affinity with  $K_i$  of 7.6  $\mu$ M for human CB2 receptors<sup>[1]</sup>. Otenabant HCl inhibits CB1 receptor with moderate unbound microsomal clearance, low hERG affinity, and adequate CNS penetration<sup>[2]</sup>.

**In Vivo:** Otenabant acutely stimulates energy expenditure in rats and decreases the respiratory quotient indicating a metabolic switch to increased fat oxidation. Otenabant (10 mg/kg, p.o.) promotes a 9%, vehicle adjusted weight loss in a 10 day weight loss study in diet-induced obese mice<sup>[1]</sup>. Otenabant HCl reverses four cannabinoid agonist-mediated behaviors (locomotor activity, hypothermia, analgesia, and catalepsy) following administration of the synthetic CB1 receptor agonist CP-55940. Otenabant HCl exhibits dose-dependent anorectic activity in a model of acute food intake in rodents and increased energy expenditure and fat oxidation<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!